Atara Biotherapeutics Inc
ATRA17.320USD
+0.150+0.87%
Market hours （ET）Quotes delayed by 15 min
124.88MMarket Cap
5.99P/E TTM
More Details of Atara Biotherapeutics Inc Company
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Atara Biotherapeutics Inc Info
Ticker SymbolATRA
Company nameAtara Biotherapeutics Inc
IPO dateOct 16, 2014
CEONguyen (Anhco)
Number of employees153
Security typeOrdinary Share
Fiscal year-endOct 16
Address1280 Rancho Conejo Blvd
CityTHOUSAND OAKS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91320
Phone18056234211
Websitehttps://www.atarabio.com/
Ticker SymbolATRA
IPO dateOct 16, 2014
CEONguyen (Anhco)
Company Executives of Atara Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
16.19K
+93.64%
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Amber Daugherty
Mr. Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Mr. Nachi Subramanian
Mr. Nachi Subramanian
Independent Director
Independent Director
--
--
Mr. James Huang
Mr. James Huang
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
16.19K
+93.64%
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Amber Daugherty
Mr. Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Panacea Venture
19.49%
Adiumentum Capital Fund I LP
17.82%
EcoR1 Capital, LLC
7.95%
Redmile Group, LLC
6.13%
The Vanguard Group, Inc.
2.82%
Other
45.80%
Shareholders
Shareholders
Proportion
Panacea Venture
19.49%
Adiumentum Capital Fund I LP
17.82%
EcoR1 Capital, LLC
7.95%
Redmile Group, LLC
6.13%
The Vanguard Group, Inc.
2.82%
Other
45.80%
Shareholder Types
Shareholders
Proportion
Venture Capital
19.49%
Investment Advisor/Hedge Fund
18.74%
Corporation
17.82%
Investment Advisor
5.08%
Individual Investor
2.76%
Hedge Fund
1.55%
Research Firm
0.93%
Other
33.64%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
178
3.30M
60.83%
+2.88K
2025Q3
215
3.30M
77.98%
+155.19K
2025Q2
228
3.18M
75.64%
+497.27K
2025Q1
266
2.68M
83.60%
-2.22M
2024Q4
282
2.41M
85.34%
-48.18K
2024Q3
301
2.46M
89.58%
-418.46K
2024Q2
322
2.88M
107.90%
-500.66K
2024Q1
338
3.38M
92.25%
-1.03M
2023Q4
339
2.70M
112.29%
-1.35M
2023Q3
338
3.64M
104.80%
-95.03K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Panacea Venture
1.41M
20.01%
+74.33K
+5.59%
Aug 15, 2025
Adiumentum Capital Fund I LP
1.28M
18.3%
+151.14K
+13.33%
May 16, 2025
EcoR1 Capital, LLC
573.18K
8.16%
--
--
Jun 30, 2025
Redmile Group, LLC
441.70K
6.29%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
190.76K
2.72%
--
--
Jun 30, 2025
Marshall Wace LLP
42.35K
0.6%
+42.35K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
65.22K
0.93%
+9.22K
+16.45%
Jun 30, 2025
Mackenzie Investments
22.51K
0.32%
+22.51K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
60.14K
0.86%
+1.46K
+2.48%
Jun 30, 2025
Acadian Asset Management LLC
65.16K
0.93%
-49.96K
-43.40%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Harbor Human Capital Factor US Small Cap ETF
0%
ProShares Hedge Replication ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Harbor Human Capital Factor US Small Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Date
Type
Ratio
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
Jun 17, 2024
Merger
25→1
FAQs
Who are the top five shareholders of Atara Biotherapeutics Inc?
The top five shareholders of Atara Biotherapeutics Inc are:
Panacea Venture holds 1.41M shares, accounting for 20.01% of the total shares.
Adiumentum Capital Fund I LP holds 1.28M shares, accounting for 18.30% of the total shares.
EcoR1 Capital, LLC holds 573.18K shares, accounting for 8.16% of the total shares.
Redmile Group, LLC holds 441.70K shares, accounting for 6.29% of the total shares.
The Vanguard Group, Inc. holds 190.76K shares, accounting for 2.72% of the total shares.
Panacea Venture holds 1.41M shares, accounting for 20.01% of the total shares.
Adiumentum Capital Fund I LP holds 1.28M shares, accounting for 18.30% of the total shares.
EcoR1 Capital, LLC holds 573.18K shares, accounting for 8.16% of the total shares.
Redmile Group, LLC holds 441.70K shares, accounting for 6.29% of the total shares.
The Vanguard Group, Inc. holds 190.76K shares, accounting for 2.72% of the total shares.
What are the top three shareholder types of Atara Biotherapeutics Inc?
The top three shareholder types of Atara Biotherapeutics Inc are:
Panacea Venture
Adiumentum Capital Fund I LP
EcoR1 Capital, LLC
Panacea Venture
Adiumentum Capital Fund I LP
EcoR1 Capital, LLC
How many institutions hold shares of Atara Biotherapeutics Inc (ATRA)?
As of 2025Q4, 178 institutions hold shares of Atara Biotherapeutics Inc, with a combined market value of approximately 3.30M, accounting for 60.83% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -17.16%.
What is the biggest source of revenue for Atara Biotherapeutics Inc?
In --, the -- business generated the highest revenue for Atara Biotherapeutics Inc, amounting to -- and accounting for --% of total revenue.
